Mesabolone is a synthetic anabolic androgen.

Plafibride is an acyl derivative of morpholinomethylurea (MMU) with clofibric acid. Plafibride is hypolipemic, platelet aggregation inhibiting agent. Plafibride did not act on the arachidonic acid metabolism. Plafibride inhibited the activity of 3',5'-cyclic AMP-phosphodiesterase, which is one of the principal mechanisms of inhibition of platelet aggregation. In the rat, plafibride inhibited significantly the spontaneously formed circulating platelet aggregates. In vitro plafibride appeared as an effective antiaggregant agent although less powerful than morpholinomethylurea, one of its presumed metabolites. The most evident secondary effects of plafibride were: a certain sedation, as a light tranquilizing agent, a hypothermic effect when it was administered at high doses, a certain beta-blocking and antiarrhythmic activity probably due to its local anesthetic action. All the side effects appeared at high doses, much higher than the therapeutic ones.

Intiquinatine is a quinolone derivative patented by Wayne State University as antineoplastic agent. Intiquinatine exhibited efficacy against early stage mammary cancer (Mam-17/Adr) and showed none of the neuromuscular toxicity.

Octaverine possesses a spasmolytic activity. Information about the current development of this compound is not available.

Eperezolid is an antibiotic agent developed for the treatment of a wide range of bacterial infections. The drug exerts its action by binding to 50 S ribosome subunit causing the inhibition of protein synthesis in bacterias. Eperezolid was tested in preclinical in vivo models of different becterial diseases in which it was shown to be active.

Dilmefone is a pharmacological agent for increasing capillary wall strength. It was developed as a coronary vasodilator.

Furnidipine, a calcium channel blocker was developed as an antihypertensive agent. It participated in clinical trials for the treatment of patients with heart failure, hypertension, and ischemic heart disorders in Spain and in Switzerland. However, all these studies were discontinued.

The information related to the biological or pharmacological application of fluprednisolone valerate is absent.

Azamethonium (known in Europe as pendiomid), a substance with the ganglia-blocking effect that was used in Europe to treat patients with acute pulmonary embolism. Information about the nowadays application of this drug is not available.

Gemcadiol is a lipid-regulating compound that was first described in 1977 in a study with hyperlipoproteinemia patients. It was concluded to be an effective antilipemic agent that is very well tolerated. Another study, conducted in 1986, showed that the compound was non-toxic in rodents, and decreased blood cholesterol. Also, liver weights were increased. Monkeys given 25 to 300 mg/kg gemcadiol for 13 weeks had slightly decreased serum cholesterol and slightly increased serum creatine phosphokinase. No effects on fetus/embryo in pregnant animals administered gemcadiol was observed in this study. No newer publications exist for this compound.